Therefore, to develop a treatment protocol that efficiently inhibits wild-type FLT3 for CML patients, we treated imatinib together with the first FDA-approved FLT3 inhibitor midostaurin. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.